Last reviewed · How we verify

NCT04905953

Comparison Of Different Doses Of Intrathecal Neostigmine In Prevention Of Post-Dural Puncture Headache

Status unknown Phase 2, PHASE3 Last updated 28 May 2021
What this trial tests

Phase 2, PHASE3 trial testing Neostigmine in Headache in 274 participants. Status unknown.

Timeline
1 February 2021
Primary endpoint
1 February 2022
1 May 2022

Quick facts

Lead sponsorCairo University
PhasePhase 2, PHASE3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment274
Start date1 February 2021
Primary completion1 February 2022
Estimated completion1 May 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 45, female only, with Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We hypothesized that; intrathecal administration of neostgmine in spinal anesthesia may have a beneficial role in reduction of the incidence or severity of PDPH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neostigmine

Trials testing the same drug.

Other recruiting trials for Headache

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04905953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing